日本北海道虻类雌性外生殖器形态(双翅目：虻科)(英文)

【目的】利用日本北海道虻类评估和验证外生殖器在分类学上的意义。【方法】将虻类成虫标本浸渍在生理盐水中并置于双目显微镜下通过针和镊子在培养皿中进行解剖并绘图,观察第9背板、第10背板、尾叶、第8腹板、受精囊、受精囊管及生殖叉器的形态特征。【结果】在日本北海道共记录了虻科(Tabanidae) 3亚科7属38种。我们观察并描述了3亚科其中的6属24种的雌性外生殖器的主要特征。亚科之间存在明显差异;然而在一般情况下属之间很难建立一种方法来确定共同点;种之间只有在斑虻属Chrysops中有相似之处,其他属中则比较多样化。因此,亚科鉴定根据第9背板、第8腹板及受精囊足以进行区分,属及种鉴定需要结合第9背板、第10背板、尾叶、第8腹板、受精囊、受精囊管及生殖叉器各自的特征组合在一起才能区分开来。我们也制作了虻类外生殖器的检索表。【结论】和许多其他昆虫一样,外生殖器是虻科的重要分类特征,对于促进分类学和系统学的发展具有重要意义。本研究首次对分布在日本北海道的虻科雌性外生殖器进行了系统研究。     

取食不同食物对小菜蛾幼虫肠道细菌多样性的影响

【目的】植食性昆虫肠道细菌的组成与其食物密切相关。本研究旨在探究小菜蛾Plutella xylostella幼虫肠道细菌多样性与其取食食物之间的关系以及它们之间相互适应的过程。【方法】本研究选取小菜蛾人工饲料品系(S)及其转寄主到结球甘蓝Brassica oleracea var. capitata、结球白菜Brassica rapa subsp. pekinensis和花椰菜Brassica olerocea var. botrytis饲养后第1代(分别为G1C, G1CC和G1WC)和第3代(分别为G3C, G3CC和G3WC)的4龄幼虫,提取小菜蛾肠道细菌基因组DNA,利用Illumina MiSeq二代高通量测序技术,分析其肠道细菌多样性和丰度。【结果】α多样性指数分析发现,取食不同食物的小菜蛾4龄幼虫肠道细菌多样性高低顺序为G1WC>G1CC>S>G1C。在菌群组成上,以人工饲料为食的S样品肠道细菌主要由厚壁菌门(Firmicutes)组成,转寄主植物后的G1C, G1CC和G1WC肠道中厚壁菌门(Firmicutes)相对丰度显著下降,G1C和G1CC小菜蛾肠道中变形菌门(Proteobacteria)相对丰度显著上升成为优势菌群,G1WC肠道中拟杆菌门(Bacteroidetes)成为优势菌群。在寄主植物上连续饲养3代后,与第1代相比,小菜蛾肠道细菌α多样性指数没有显著性改变,但在结球甘蓝和结球白菜上小菜蛾肠道菌群结构却发生了变化,相比G1C,G3C肠道中芽孢杆菌目(Bacillales)的相对丰度显著下降;相比G1CC, G3CC肠道中放线菌门(Proteobacteria)、芽单胞菌门(Gemmatimonadetes)和硝化螺旋菌门(Nitrospirae)的相对丰度均显著上升。【结论】取食人工饲料和不同寄主植物的小菜蛾幼虫肠道细菌多样性和群落构成存在显著差异,寄主植物对小菜蛾肠道微生物的结构组成具有重要的影响,且小菜蛾肠道微生物对寄主植物可能存在一个长期适应的过程。本研究为进一步探讨影响小菜蛾肠道细菌变化的因素,以及后续研究肠道细菌与寄主植物之间的互作奠定了良好的基础。     

昆虫足的附着机制

昆虫卓越的爬行和附着能力来源于其精细的功能性黏附系统。根据形态结构的不同,昆虫的黏附系统可分为光滑型黏附垫和刚毛型黏附垫两种类型,二者在分泌液的支持下均能附着于几乎所有的光滑或粗糙的物体表面,而且这两种类型的黏附垫与界面的附着的形成均主要依赖于范德华力。本文综述了昆虫足的附着机制,包括光滑型和刚毛型两种黏附垫的结构和其形成附着的机理,以及黏附垫分泌液的功能、组成成分和释放机制,阐明了昆虫如何巧妙地解决稳定附着和快速脱附这一矛盾的问题,讨论了诸如界面的理化性质和环境湿度等环境因素对昆虫附着的影响,以期帮助人们深入地理解昆虫足的附着机制,并为其在仿生学等方面的应用提供理论依据。     

钙、硅对酸雨胁迫下小麦生长和养分吸收的影响

采用盆栽试验方法研究了在模拟酸雨胁迫下施用碳酸钙和硅酸钠对红壤酸化、土壤活性铝和速效养分含量以及小麦生长、养分吸收与积累的影响。结果表明,短期内(2个月)喷施pH3.0的酸雨对红壤酸化有一定的促进作用,但对小麦生长无显着不良影响,反而因酸雨中含有N、S、K等营养元素,可起到一定的促进作用。施用碳酸钙和硅酸钠具有抑制土壤酸化、降低活性铝的作用,但碳酸钙用量应控制在2.0g·kg^-1以下,否则将降低土壤磷的生物有效性,抑制小麦生长。与此相反,硅酸钠的施用则大幅度提高土壤有效磷含量,促进小麦对P的吸收和利用,同时也有利于N、K等元素的利用,从而显着促进作物生长。此外,Si还具有显着提高作物抗麦蚜危害的能力.     

白蚁信息素研究进展

采用信息素防治白蚁这种世界性害虫是当前白蚁研究的一大热点。本文从化学和生物两个方面总结了几十年来国内外白蚁信息素及其类似物研究进展。讨论了影响信息素活性的几个因素。并根据最新的研究情况,对今后的信息素及其类似物的理论研究和应用情况进行了展望。     

白蚁信息素研究进展

白蚁是最古老的社会性昆虫, 其社会性的维持需要信息素的相互作用。本文回顾了近年来国内外白蚁信息素研究的最新进展, 内容涉及白蚁踪迹信息素、 性信息素、 告警信息素和促食信息素的功能、 化学成分及产生信息素的外分泌腺。白蚁分泌信息素的腺体主要有背板腺、 腹板腺、 后腹板腺、 额腺和唾腺。绝大多数白蚁信息素是挥发性物质。白蚁在化学通讯上存在节俭策略, 即同一种化合物由不同的白蚁种类的不同外分泌腺分泌, 可具有不同的功能。总结了各类信息素在白蚁物种间、 同一物种的品级间和性别间的异同和作用方式, 强调了白蚁信息素的反应阈值、 最佳浓度、 有效期和物种特异性对其功能的影响。目前对白蚁信息素的研究尚处于起步阶段, 其研究成果对等翅目系统发育研究和白蚁防治具有重要的意义。文章最后展望了白蚁信息素在白蚁防治上的应用前景。     

骨诱导因子-一种新的细胞生长因子

美国Collagen公司称:它们发现了一种新的细胞生长因子,这种因子和转化生长因子β (Transfurming Growth Factor beta(TGFb))合用,可促进骨生长。因之称这种新细胞生长因子为骨诱导因子(Osteoinductive Factor(OIF))。     

肌肽通过调节JNK和NF-kappaB通路抑制高糖诱导的心肌细胞凋亡

高血糖症是糖尿病并发心血管疾病的重要危险因素. 高血糖诱导产生的活性氧（ROS）能够引起糖尿病心肌病.我们的前期工作已经证实,肌肽对高糖环境下细胞凋亡具有保护作用,但其机制尚未明确.为研究肌肽对高糖诱导的大鼠心肌细胞凋亡的抑制作用及相关信号机制,以高糖诱导心肌细胞H9c2为模型,采用Brdu-ELISA法检测细胞增殖过程中DNA合成情况,流式细胞术检测细胞凋亡率,免疫印迹实验检测JNK/c-Jun、NF-κB的磷酸化水平,RT-PCR检测TNF-α的mRNA表达. 实验结果显示,肌肽能够提高高糖损伤的H9c2细胞增殖能力,降低心肌细胞凋亡,抑制高糖激活的JNK、c-Jun和NF-κB磷酸化水平及TNFα的mRNA表达. 上述结果表明,肌肽拮抗高糖诱导的心肌细胞凋亡机制与抑制p-JNK /p-c-Jun、p-NF-κB水平和TNF-α表达有关.     

“七五”攻关期间我国医药生物技术产品研究开发进展

医药生物技术做为当今生物技术的主要研究领域之一已取得了令人瞩目的成就。在美国,目前投放市场的生物技术产品绝大部分为医药产品,它们的开发具有速度快、产品数量多、疾病谱广、经济效益显著等特点。我国政府对医药生物技术的研究开发给予了高度的重视,据不完全统计,“七五”攻关期间组织了1200多人的研究队伍,投入了3500多万元的科研经费进行医药生物技术的研究开发工作。     

弗里熊蜂蜜罐中糖液成分分析

【目的】熊蜂是众多植物的重要传粉昆虫,以采集并贮藏花蜜和花粉为主要食物。本研究旨在探究熊蜂的营养需求及明确其对采集的食物是否存在酿制过程。【方法】利用白砂糖溶液(糖浓度50%)饲喂弗里熊蜂Bombus friseanus蜂群,收集并检测其贮藏在蜜罐中1~7 d的糖液,作为处理组样品;同时将上述白砂糖溶液置于灭菌离心管中,排除熊蜂取食,作为对照组样品,测定贮藏期间处理组和对照组糖液的pH值、糖浓度、糖组分及α-淀粉酶和转化酶活性。【结果】弗里熊蜂B. friseanus贮藏在蜜中1~7d的糖液pH值平均为3.74±0.13,显著低于对照组(6.55±0.15);糖浓度与贮藏时间显著正相关,贮藏6d后糖浓度显著高于贮藏1~3 d时的;糖液组分更加丰富,除蔗糖外利用HPLC还检出果糖、葡萄糖、麦芽糖和海藻糖,贮藏4~5 d的糖液中己糖含量极显著高于贮藏1~3 d和6~7 d时的,己糖和麦芽糖含量分别与蔗糖含量极显著负相关,总糖中果糖和麦芽糖含量与贮藏时间极显著负相关,葡萄糖、蔗糖和海藻糖的含量分别与贮藏时间极显著正相关。贮藏6 d的糖液中α-淀粉酶活性显著高于其他时间,其他贮藏时间样品间α-淀粉酶活性差异不显著,而所有样本的转化酶活性在21.17~38.05 U/g FW之间,随贮藏时间的延长差异不显著。【结论】弗里熊蜂B. friseanus采集人工饲喂的糖溶液贮藏在蜜罐中,经其加工后发生了物理和生物化学变化,揭示熊蜂存在酿蜜能力。本研究的结果为熊蜂生物学及繁育研究提供了参考。     

Hyaluronidase increases the biodistribution of acid alpha-1,4 glucosidase in the muscle of Pompe disease mice: an approach to enhance the efficacy of enzyme replacement therapy

Pompe disease (glycogen storage disease type II) is a glycogen storage disease caused by a deficiency of the lysosomal enzyme, acid maltase/acid alpha-1,4 glucosidase (GAA). Deficiency of the enzyme leads primarily to intra-lysosomal glycogen accumulation, primarily in cardiac and skeletal muscles, due to the inability of converting glycogen into glucose. Enzyme replacement therapy (ERT) has been applied to replace the deficient enzyme and to restore the lost function. However, enhancing the enzyme activity to the muscle following ERT is relatively insufficient. In order to enhance GAA activity into the muscle in Pompe disease, efficacy of hyaluronidase (hyase) was examined in the heart, quadriceps, diaphragm, kidney, and brain of mouse model of Pompe disease. Administration of hyase 3000 U/mouse (intravenous) i.v. or i.p. (intraperitoneal) and 10 min later recombinant human GAA (rhGAA) 20 mg/kg i.v. showed more GAA activity in hyase i.p. injected mice compared to those mice injected with hyase via i.v. Injection of low dose of hyase (3000 U/mouse) or high dose of hyase (10,000 U/mouse) i.p. and 20 min or 60 min later 20 mg/kg rhGAA i.v. increased GAA activity into the heart, diaphragm, kidney, and quadriceps compared to hyase untreated mice. These studies suggest that hyase enhances penetration of enzyme into the tissues including muscle during ERT and therefore hyase pretreatment may be important in treating Pompe disease.     

Glycogen storage in multiple muscles of old GSD-II mice can be rapidly cleared after a single intravenous injection with a modified adenoviral vector expressing hGAA

BACKGROUND: Glycogen storage disease II (GSD-II) is an autosomal recessive lysosomal storage disease, due to acid-alpha-glucosidase (GAA) deficiency. The disease is characterized by massive glycogen accumulation in the cardiac and skeletal muscles. There is early onset (infantile, also known as Pompe disease) as well as late onset (juvenile and adult) forms of GSD-II. Few studies have been published to date that have explored the consequences of delivering a potential therapy to either late onset GSD-II subjects, and/or early onset patients with long-established muscle pathology. One recent report utilizing GAA-KO mice transgenically expressing human GAA (hGAA) suggested that long-established disease in both cardiac and skeletal muscle is likely to prove resistant to therapies. To investigate the potential for disease reversibility in old GSD-II mice, we studied their responsiveness to exogenous hGAA exposure via a gene therapy approach that we have previously shown to be efficacious in young GAA-KO mice. METHODS: An [E1-, polymerase-] adenoviral vector encoding hGAA was intravenously injected into two groups of aged GAA-KO mice; GAA expression and tissue glycogen reduction were evaluated. RESULTS: After vector injection, we found that extremely high amounts of hepatically secreted hGAA could be produced, and subsequently taken up by multiple muscle tissues in the old GAA-KO mice by 17 days post-injection (dpi). As a result, all muscle groups tested in the old GAA-KO mice showed significant glycogen reductions by 17 dpi, relative to that of age-matched, but mock-injected GAA-KO mice. For example, glycogen reduction in heart was 84%, in quadriceps 46%, and in diaphragm 73%. Our data also showed that the uptake and the subsequent intracellular processing of virally expressed hGAA were not impaired in older muscles. CONCLUSIONS: Overall, the previously reported 'resistance' of old GAA-KO muscles to exogenous hGAA replacement approaches can be rapidly overcome after a single intravenous injection with a modified adenoviral vector expressing hGAA.     

Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance

Pompe disease, which results from mutations in the gene encoding the glycogen-degrading lysosomal enzyme acid alpha -glucosidase (GAA) (also called "acid maltase"), causes death in early childhood related to glycogen accumulation in striated muscle and an accompanying infantile-onset cardiomyopathy. The efficacy of enzyme replacement therapy (ERT) with recombinant human GAA was demonstrated during clinical trials that prolonged subjects' overall survival, prolonged ventilator-free survival, and also improved cardiomyopathy, which led to broad-label approval by the U.S. Food and Drug Administration. Patients who lack any residual GAA expression and are deemed negative for cross-reacting immunologic material (CRIM) have a poor response to ERT. We previously showed that gene therapy with an adeno-associated virus (AAV) vector containing a liver-specific promoter elevated the GAA activity in plasma and prevented anti-GAA antibody formation in immunocompetent GAA-knockout mice for 18 wk, predicting that liver-specific expression of human GAA with the AAV vector would induce immune tolerance and enhance the efficacy of ERT. In this study, a very low number of AAV vector particles was administered before initiation of ERT, to prevent the antibody response in GAA-knockout mice. A robust antibody response was provoked in naive GAA-knockout mice by 6 wk after a challenge with human GAA and Freund's adjuvant; in contrast, administration of the AAV vector before the GAA challenge prevented the antibody response. Most compellingly, the antibody response was prevented by AAV vector administration during the 12 wk of ERT, and the efficacy of ERT was thereby enhanced. Thus, AAV vector-mediated gene therapy induced a tolerance to introduced GAA, and this strategy could enhance the efficacy of ERT in CRIM-negative patients with Pompe disease and in patients with other lysosomal storage diseases.     

Glycosylation-independent Lysosomal Targeting of Acid α-Glucosidase Enhances Muscle Glycogen Clearance in Pompe Mice

We have used a peptide-based targeting system to improve lysosomal delivery of acid α-glucosidase (GAA), the enzyme deficient in patients with Pompe disease. Human GAA was fused to the glycosylation-independent lysosomal targeting (GILT) tag, which contains a portion of insulin-like growth factor II, to create an active, chimeric enzyme with high affinity for the cation-independent mannose 6-phosphate receptor. GILT-tagged GAA was taken up by L6 myoblasts about 25-fold more efficiently than was recombinant human GAA (rhGAA). Once delivered to the lysosome, the mature form of GILT-tagged GAA was indistinguishable from rhGAA and persisted with a half-life indistinguishable from rhGAA. GILT-tagged GAA was significantly more effective than rhGAA in clearing glycogen from numerous skeletal muscle tissues in the Pompe mouse model. The GILT-tagged GAA enzyme may provide an improved enzyme replacement therapy for Pompe disease patients.     

Induction of Tolerance to a Recombinant Human Enzyme,Acid Alpha-Glucosidase,in Enzyme Deficient Knockout Mice

When knockout mice are used to test the efficacy of recombinant human proteins, the animals often develop antibodies to the enzyme, precluding long-term pre-clinical studies. This has been a problem with a number of models, for example, the evaluation of gene or enzyme replacement therapies in a knockout model of glycogen storage disease type II (GSDII; Pompe syndrome). In this disease, the lack of acid alpha-glucosidase (GAA) results in lysosomal accumulation of glycogen, particularly in skeletal and cardiac muscle. Here, we report that in a GAA-deficient mouse model of GSDII, low levels of transgene-encoded human GAA expressed in skeletal muscle or liver dramatically blunt or abolish the immune response to human recombinant protein. Of two low expression transgenic lines, only the liver-expressing line exhibited a profound GAA deficiency in skeletal muscle and heart indistinguishable from that in the original knockouts. The study suggests that the induction of tolerance in animal models of protein deficiencies could be achieved by restricting the expression of a gene of interest to a particular, carefully chosen tissue.     

The Pharmacological Chaperone AT2220 Increases the Specific Activity and Lysosomal Delivery of Mutant Acid Alpha-Glucosidase,and Promotes Glycogen Reduction in a Transgenic Mouse Model of Pompe Disease

Pompe disease is an inherited lysosomal storage disorder that results from a deficiency in acid α-glucosidase (GAA) activity due to mutations in the GAA gene. Pompe disease is characterized by accumulation of lysosomal glycogen primarily in heart and skeletal muscles, which leads to progressive muscle weakness. We have shown previously that the small molecule pharmacological chaperone AT2220 (1-deoxynojirimycin hydrochloride, duvoglustat hydrochloride) binds and stabilizes wild-type as well as multiple mutant forms of GAA, and can lead to higher cellular levels of GAA. In this study, we examined the effect of AT2220 on mutant GAA, in vitro and in vivo, with a primary focus on the endoplasmic reticulum (ER)-retained P545L mutant form of human GAA (P545L GAA). AT2220 increased the specific activity of P545L GAA toward both natural (glycogen) and artificial substrates in vitro. Incubation with AT2220 also increased the ER export, lysosomal delivery, proteolytic processing, and stability of P545L GAA. In a new transgenic mouse model of Pompe disease that expresses human P545L on a Gaa knockout background (Tg/KO) and is characterized by reduced GAA activity and elevated glycogen levels in disease-relevant tissues, daily oral administration of AT2220 for 4 weeks resulted in significant and dose-dependent increases in mature lysosomal GAA isoforms and GAA activity in heart and skeletal muscles. Importantly, oral administration of AT2220 also resulted in significant glycogen reduction in disease-relevant tissues. Compared to daily administration, less-frequent AT2220 administration, including repeated cycles of 4 or 5 days with AT2220 followed by 3 or 2 days without drug, respectively, resulted in even greater glycogen reductions. Collectively, these data indicate that AT2220 increases the specific activity, trafficking, and lysosomal stability of P545L GAA, leads to increased levels of mature GAA in lysosomes, and promotes glycogen reduction in situ. As such, AT2220 may warrant further evaluation as a treatment for Pompe disease.     

The pharmacological chaperone AT2220 increases recombinant human acid α-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease

Pompe disease is an inherited lysosomal storage disease that results from a deficiency in the enzyme acid α-glucosidase (GAA), and is characterized by progressive accumulation of lysosomal glycogen primarily in heart and skeletal muscles. Recombinant human GAA (rhGAA) is the only approved enzyme replacement therapy (ERT) available for the treatment of Pompe disease. Although rhGAA has been shown to slow disease progression and improve some of the pathophysiogical manifestations, the infused enzyme tends to be unstable at neutral pH and body temperature, shows low uptake into some key target tissues, and may elicit immune responses that adversely affect tolerability and efficacy. We hypothesized that co-administration of the orally-available, small molecule pharmacological chaperone AT2220 (1-deoxynojirimycin hydrochloride, duvoglustat hydrochloride) may improve the pharmacological properties of rhGAA via binding and stabilization. AT2220 co-incubation prevented rhGAA denaturation and loss of activity in vitro at neutral pH and 37°C in both buffer and blood. In addition, oral pre-administration of AT2220 to rats led to a greater than two-fold increase in the circulating half-life of intravenous rhGAA. Importantly, co-administration of AT2220 and rhGAA to GAA knock-out (KO) mice resulted in significantly greater rhGAA levels in plasma, and greater uptake and glycogen reduction in heart and skeletal muscles, compared to administration of rhGAA alone. Collectively, these preclinical data highlight the potentially beneficial effects of AT2220 on rhGAA in vitro and in vivo. As such, a Phase 2 clinical study has been initiated to investigate the effects of co-administered AT2220 on rhGAA in Pompe patients.     

Mass spectrometric quantification of glycogen to assess primary substrate accumulation in the Pompe mouse

Glycogen storage in the α-glucosidase knockout((6neo/6neo)) mouse recapitulates the biochemical defect that occurs in the human condition; as such, this mouse serves as a model for the inherited metabolic deficiency of lysosomal acid α-glucosidase known as Pompe disease. Although this model has been widely used for the assessment of therapies, the time course of glycogen accumulation that occurs as untreated Pompe mice age has not been reported. To address this, we developed a quantitative method involving amyloglucosidase digestion of glycogen and quantification of the resulting free glucose by liquid chromatography/electrospray ionization-tandem mass spectrometry. The method was sensitive enough to measure as little as 0.1 μg of glycogen in tissue extracts with intra- and interassay coefficients of variation of less than 12%. Quantification of glycogen in tissues from Pompe mice from birth to 26 weeks of age showed that, in addition to the accumulation of glycogen in the heart and skeletal muscle, glycogen also progressively accumulated in the brain, diaphragm, and skin. Glycogen storage was also evident at birth in these tissues. This method may be particularly useful for longitudinal assessment of glycogen reduction in response to experimental therapies being trialed in this model.     

基于TCID50检测AAV9载体制品感染性滴度的方法

目的:建立一种基于半数组织培养感染剂量(median tissue culture infective dose,TCID₅₀)检测9型腺相关病毒(adeno-associated virus type 9,AAV9)载体制品感染性滴度的方法。方法:利用含AAV2 rep和cap基因的1型单纯疱疹病毒(herpes simplex virus type1,HSV1)做为辅助病毒与梯度稀释的AAV9载体制品共同感染HEK-293细胞,培养48 h后用实时荧光定量PCR(quantitative real-time PCR,qPCR)扩增AAV特异性反向末端重复序列(inverted terminal repeats,ITR),根据阳性及阴性感染孔数,利用Kärber法计算样品的TCID₅₀。结果:采用携带增强绿色荧光蛋白报告基因的AAV9载体制品确定辅助病毒HSV1-rc最佳感染复数(multiplicity of infection,MOI)为5,AAV9-101的感染性滴度为1.6×10⁹ TCID₅₀/mL。结论:对AAV9载体制品进行感染性滴度检测,且具有可重复性。     

Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorder—murine Pompe disease

Autophagy, an intracellular system for delivering portions of cytoplasm and damaged organelles to lysosomes for degradation/recycling, plays a role in many physiological processes and is disturbed in many diseases. We recently provided evidence for the role of autophagy in Pompe disease, a lysosomal storage disorder in which acid alphaglucosidase, the enzyme involved in the breakdown of glycogen, is deficient or absent. Clinically the disease manifests as a cardiac and skeletal muscle myopathy. The current enzyme replacement therapy (ERT) clears lysosomal glycogen effectively from the heart but less so from skeletal muscle. In our Pompe model, the poor muscle response to therapy is associated with the presence of pools of autophagic debris. To clear the fibers of the autophagic debris, we have generated a Pompe model in which an autophagy gene, Atg7, is inactivated in muscle. Suppression of autophagy alone reduced the glycogen level by 50–60%. Following ERT, muscle glycogen was reduced to normal levels, an outcome not observed in Pompe mice with genetically intact autophagy. The suppression of autophagy, which has proven successful in the Pompe model, is a novel therapeutic approach that may be useful in other diseases with disturbed autophagy.